TOP > News Release > Corporate
News Release

New Release Browse by Category

Corporate News Release

RSS
Browse by Year
2012
2011
2010
2009
2008
2007
2006
2005
Browse by Category
Corporate
R&D
Products
Others

2012

2012.01.26 Corporate
RANBAXY ANNOUNCES COURT FILING OF CONSENT DECREE WITH U.S. FOOD AND DRUG ADMINISTRATION

2011

2011.12.21 Corporate
Ranbaxy to Market Daiichi Sankyo’s Innovative Products in Malaysia Strategic Alliance Harnesses Synergies in ASEAN
2011.12.21 Corporate
RANBAXY ANNOUNCES CONSENT DECREE WITH U.S. FOOD AND DRUG ADMINISTRATION TAKES CORRECTIVE STEPS, COMMITS TO FURTHER MEASURES
2011.11.18 Corporate
Daiichi Sankyo Establishes New Subsidiary in China
2011.11.10 Corporate
Daiichi Sankyo To License ARQ 092 from ArQule, the First New Compound Resulting from the Companies’ Joint AKIP Research Collaboration
2011.11.08 Corporate
Daiichi Sankyo Brasil and Kyorin Pharmaceutical Reach Agreement in Brazil for Activities Related to the Development and Marketing of Imidafenacin
2011.08.02 Corporate
Daiichi Sankyo and Ranbaxy to Expand Hybrid Business Model in Mexico
2011.05.24 Corporate
Daiichi Sankyo and AstraZeneca Announce a Co-Promotion Agreement in Japan for Denosumab, a Treatment of Bone Disorders stemming from Bone Metastasis
2011.05.12 Corporate
DAIICHI SANKYO Announces New Executive Candidates
2011.04.21 Corporate
Fourth Update on Daiichi Sankyo Operations Following the Great East Japan Earthquake
2011.04.08 Corporate
Third Update on Daiichi Sankyo Operations Following the Great East Japan Earthquake
2011.03.31 Corporate
Kitasato Daiichi Sankyo Vaccine Joint Venture Company to Begin Operations
2011.03.25 Corporate
Update on Daiichi Sankyo Operations Following the Tohoku Pacific Offshore Earthquake
2011.03.14 Corporate
Daiichi Sankyo Operations Following the Tohoku Pacific Offshore Earthquake
2011.03.01 Corporate
Daiichi Sankyo to Leverage Ranbaxy’s Network to Market Its Innovative Products in Singapore
2011.03.01 Corporate
Plexxikon Inc. To Join Daiichi Sankyo Group
2011.02.16 Corporate
Daiichi Sankyo, Inc.Acquires First US-Based Packaging and Manufacturing Facility

2010

2010.12.13 Corporate
Luitpold Pharmaceuticals, Inc. Acquires ROXRO PHARMA, Inc., a U.S. Company Developing Acute Pain Products
2010.11.30 Corporate
Joint Venture Company between Daiichi Sankyo and The Kitasato Institute to be Established and Begin Operations on April 1, 2011
2010.09.30 Corporate
Daiichi Sankyo Espha Begins Operations in Japan to Sell Generics and Long-listed, Off-patent Pharmaceuticals with Proven Market Presence
2010.09.15 Corporate
Result of the Open Offer for Shares in Zenotech Laboratories Limited
2010.08.19 Corporate
Notice of Details of the Stock Options (Stock Acquisition Rights)
2010.08.12 Corporate
Announcement on Change in Ranbaxy Executive Leadership
2010.08.04 Corporate
Notice of Commencing Open Offer for Shares in Zenotech Laboratories Limited
2010.07.30 Corporate
Announcement Regarding the Establishment of a Joint Venture Company between Daiichi Sankyo and The Kitasato Institute
2010.07.30 Corporate
Daiichi Sankyo Ends Shareholder Agreement with Sanofi Pasteur S.A.
2010.07.21 Corporate
Daiichi Sankyo to Leverage Ranbaxy's Network to Market Its Innovative Antibiotic Tavanic® (Levofloxacin) in Romania and South Africa
2010.07.02 Corporate
Daiichi Sankyo and Ranbaxy to Integrate New Drug Research and Development System
2010.06.10 Corporate
Ranbaxy Launches Antiplatelet Agent Prasugrel in India
2010.05.12 Corporate
Daiichi Sankyo Announces New Executive Candidates
2010.03.12 Corporate
Daiichi Sankyo Announces Second Mid-term Business Management Plan (FY 2010-2012)
2010.03.05 Corporate
Daiichi Sankyo Appoints New Board Position at each Subsidiary
2010.02.26 Corporate
Daiichi Sankyo Group to Expand its Business Scope in Japan through Establishment of Daiichi Sankyo Espha Co., Ltd.
2010.02.26 Corporate
Daiichi Sankyo Announces Organizational Restructuring as of April 1, 2010
2010.02.26 Corporate
Daiichi Sankyo Appoints New Board Position at each Subsidiary
2010.02.26 Corporate
Daiichi Sankyo Appoints New Corporate Officers
2010.02.10 Corporate
Daiichi Sankyo to Launch Innovator Products in Mexico through Ranbaxy
Companies to Fully Leverage the Synergistic Power of the Hybrid Business Model
2010.01.06 Corporate
Luitpold Pharmaceuticals Inc. Acquires PharmaForce, Inc., a U.S. Specialty Injectable Pharmaceutical Company

2009

2009.12.21 Corporate
Daiichi Sankyo to Leverage Ranbaxy's Presence in Africa for Marketing and Distribution Olmesartan to be launched in six African countries
2009.10.05 Corporate
Daiichi Sankyo to Leverage Ranbaxy's Presence in Mexico for Marketing and Distribution
New Division will bring Daiichi Sankyo's innovator products to Mexican market
2009.09.01 Corporate
Daiichi Sankyo and Ranbaxy Leverage New Business Model with Launch of EVISTA in Romania
2009.08.17 Corporate
Notice of Details of the Stock Options (Stock Acquisition Rights)
2009.07.31 Corporate
DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
2009.05.24 Corporate
Daiichi Sankyo and Ranbaxy Announce Reconstitution of Ranbaxy Executive Leadership
2009.05.12 Corporate
DAIICHI SANKYO Announces New Executive Candidates
2009.03.31 Corporate
Ranbaxy to Launch Daiichi Sankyo’s innovative antihypertensive, Olvance, in India
2009.02.26 Corporate
Ranbaxy Receives a Letter from the U.S. FDA Related to Paonta Sahib Facility
2009.02.26 Corporate
Daiichi Sankyo's response to recent FDA letter to Ranbaxy(Second Issue)
2009.02.20 Corporate
DAIICHI SANKYO Announces the Corporate Officers for FY2009
2009.02.20 Corporate
DAIICHI SANKYO Notice on Organizational Restructuring as of April 1, 2009
2009.02.12 Corporate
Partial Correction to Consolidated Financial Results for the Third Quarter of the Fiscal Year Ending March 31, 2009
(Correction of Text and Figures)
2009.01.19 Corporate
Notice regarding the acquisition of shares in Zenotech Laboratories Limited
2009.01.08 Corporate
Daiichi Sankyo, Inc. Establishes Subsidiary in Puerto Rico
2009.01.05 Corporate
DAIICHI SANKYO Records Valuation Loss, Goodwill Write-down, on Investment in Ranbaxy Laboratories

2008

2008.12.19 Corporate
Ranbaxy Reconstitutes Board of Directors following Strategic Alliance with Japan’s Daiichi Sankyo

Ranbaxy CEO and Managing Director Malvinder Mohan Singh Takes Additional Role as Chairman of the Board
2008.11.26 Corporate
DAIICHI SANKYO sets up subsidiary in Ireland
Critical step in European expansion
2008.11.17 Corporate
DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options (Stock Acquisition Rights) as Remuneration
2008.11.07 Corporate
Ranbaxy and Daiichi Sankyo Successfully Complete Landmark Deal
2008.10.31 Corporate
DAIICHI SANKYO to Issue Stock Options (Stock Acquisition Rights) as Remuneration
2008.10.31 Corporate
DAIICHI SANKYO to Dissolve Subsidiaries with Sanofi-aventis
2008.10.23 Corporate
UK Levofloxacin SPC and Underlying Patent Upheld by High Court Patent Court
2008.10.20 Corporate
Daiichi Sankyo and Ranbaxy Move Forward Toward
The Completion of the Landmark Deal
2008.10.17 Corporate
Result of the Open Offer for Shares in Ranbaxy Laboratories Limited
2008.09.24 Corporate
Notice regarding The Open Offer for Shares in Ranbaxy Laboratories Limited
2008.08.29 Corporate
DAIICHI SANKYO Announces Cancellation of Treasury Stocks
2008.08.11 Corporate
DAIICHI SANKYO to Launch Open Offer for Ranbaxy Laboratories Limited
2008.08.04 Corporate
DAIICHI SANKYO Announces Results of Share Buyback
2008.07.09 Corporate
Luitpold Pharmaceuticals/American Regent and Fresenius Medical Care sign
agreements for exclusive sublicense of Venofer(R)in U.S.
2008.06.27 Corporate
DAIICHI SANKYO to Acquire Own Shares
2008.06.11 Corporate
Ranbaxy to bring in Daiichi Sankyo as Majority Partner
Strategic Combination creates Innovator and Generic Pharma Powerhouse
2008.05.21 Corporate
Daiichi Sankyo Co., Ltd. Announces Acquisition of Biotech Firm U3 Pharma AG
2008.05.13 Corporate
DAIICHI SANKYO COMPANY Announces Executive-Change Candidate
2008.05.13 Corporate
Expansion of Business into Turkey and India
2008.03.31 Corporate
Study Results Show Investigational Drug, Prasugrel, Cuts Risk of Stent-Related Clots by More than Half Versus Clopidogrel
2008.03.05 Corporate
Japanese pharmaceutical company acquires osteoporosis medication EVISTA from Lilly
DAIICHI SANKYO presses ahead with European expansion
2008.02.15 Corporate
DAIICHI SANKYO Notice concerning Determination of Certain Terms of the Issue Stock Options
(Stock Acquisition Rights) as Remuneration

2007

2007.11.30 Corporate
Share Transfer of NIPPON NYUKAZAI and SINO-JAPAN CHEMICAL
(subsidiaries of DAIICHI SANKYO)
2007.10.26 Corporate
DAIICHI SANKYO Announces the Revisions of Financial Forecasts for FY2007
2007.08.22 Corporate
Daiichi Sankyo and Forest Laboratories Sign Letter of Intent for Co-Promotion of AZOR™
2007.07.31 Corporate
DAIICHI SANKYO Announces Results of Share Buyback
2007.06.01 Corporate
DAIICHI SANKYO to Acquire Own Shares
2007.05.25 Corporate
DAIICHI SANKYO to award stock options as remuneration
2007.05.15 Corporate
DAIICHI SANKYO COMPANY Announces Executive-Change Candidates
2007.05.08 Corporate
Consolidated forecast for FY2007
2007.04.27 Corporate
Revisions of Earnings Forecasts for FY 2006
2007.02.14 Corporate
DAIICHI SANKYO Announces Midterm Management Plan for Fiscal 2007-2009

2006

2006.11.06 Corporate
Announcement of new corporate officers
2006.10.27 Corporate
Revisions of earnings forecasts for 1H FY 2006
2006.10.23 Corporate
Canadian Levofloxacin Patent Upheld by Federal Judge
2006.10.10 Corporate
Daiichi Pharmaceutical Korea to Become Wholly Owned Subsidiary of Daiichi Pharmaceutical Co., Ltd.
2006.09.08 Corporate
DAIICHI SANKYO to Invest in the Healthcare Venture Fund
2006.08.31 Corporate
Sankyo and Ajinomoto Reach Agreement on the Development, Manufacture and Marketing of the New Diabetes Drug, AJD101
2006.08.03 Corporate
Daiichi Wins FLOXIN® Otic Patent Challenge by Generic Manufacturer Apotex
2006.08.02 Corporate
Sales of Antihypertensive Agent Olmetec® Begin in China
2006.07.14 Corporate
Sankyo's European Subsidiaries' Names Change
2006.06.16 Corporate
Sankyo's Chinese Subsidiary Acquires Medicine Management Certificate
2006.05.26 Corporate
DAIICHI SANKYO to Reduce Capital Reserves
2006.05.26 Corporate
DAIICHI SANKYO to Amend the Articles of Incorporation
2006.03.30 Corporate
Announcement of Revisions to Sankyo's Consolidated Financial Results for Prior Fiscal Years
2006.03.30 Corporate
Announcement of Revisions to Consolidated Financial Results for the Interim Period of Fiscal 2005
(Six-Month Period Ended September 30, 2005)
2006.03.28 Corporate
Announcement of the First DAIICHI SANKYO Group R&D Meeting
2006.03.23 Corporate
American Subsidiaries of Daiichi Pharmaceutical and Sankyo to Integrate
2006.03.23 Corporate
Sankyo and Exelixis Sign Joint Research Agreement
2006.02.17 Corporate
Future Business Prospects of the Hyperlipidemia Drug Pravastatin in the United States
2006.01.10 Corporate
KAI Pharmaceuticals, Inc. and Sankyo Company, Limited Enter Global Alliance to Develop and Commercialize Novel Compounds for Cardiovascular Disease

2005

2005.12.22 Corporate
Daiichi Defeats Mylan in Dispute Over $1 Billion Per Year Drug Patent
2005.12.14 Corporate
Transfer of a Portion of Sankyo Pharma GmbH Products
2005.09.28 Corporate
Establishment of DAIICHI SANKYO COMPANY, LIMITED
Browse by Year
2012
2011
2010
2009
2008
2007
2006
2005
Browse by Category
Corporate
R&D
Products
Others